Quick, Sensitive Detection of Alzheimer's Disease Biomarkers using Multiplexing
11 Dec 2017
In a poster presentation at the Neuroscience 2017 conference, Dr. Anthony Saporita, senior scientist at MilliporeSigma, explains how multiplex technology can be applied to detect biomarkers in Alzheimer’s disease. He further discusses the launch of the highly sensitive SMC kits for Aβ42 detection in human CSF and plasma.
Related Products
Request Quote for All Products
MILLIPLEX® MAP Human Amyloid Beta and Tau Magnetic Bead Panel - Multiplex Assay
MerckThe MILLIPLEX ® MAP Human Amyloid Beta and Tau Panel is a 4-plex kit containing all reagents needed for simultaneous quantification of Aß40, Aß42, Total Tau proteins (tTau), and Phosphorylated Tau Thr181 (pTau181) in CSF samples
MILLIPLEX® MAP Human Neuroscience Magnetic Bead Panel 1 - Neuroscience Multiplex Assay
MerckThe analytes available for this multiplex kit are: a-Synuclein, TG2 (Transglutaminase 2), GFAP (Glial Fibrillary Acidic Protein), UCH1 (Ubiquitin carboxyl-terminal hydrolase isozyme L1 or PARK5), DJ1 (Parkinson's Disease Protein 7) and NSE (Neuron Specific Enolase synuclein)
SMCxPRO™ Immunoassay System
MerckDetect low-abundant proteins at the femtogram/mL level with the sensitivity and speed of the SMCxPRO™ immunoassay system – a powerful, compact and affordably priced protein quantifier. Discovery depends on detection. When the success of your research requires finding and quantifying low-level proteins, you need equipment you can rely on to detect your target. This compact, benchtop instrument will fit seamlessly into your workflow and offers: High sensitivity (femtogram/mL level) Rapid analysis Bead-based kits Compact: 14” W X 16” H X 17.5” D Access to over 600 antibody pairs Count on the SMCxPRO™ immunoassay system to quantify low-abundant proteins with rapid precision.
